Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization

A recent clinical trial of a T-cell-based AIDS vaccine delivered with recombinant adenovirus type 5 (rAd5) vectors showed no efficacy in lowering viral load and was associated with increased risk of human immunodeficiency virus type 1 (HIV-1) infection. Preexisting immunity to Ad5 in humans could th...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Cheng, Cheng, Gall, Jason G. D., Nason, Martha, King, C. Richter, Koup, Richard A., Roederer, Mario, McElrath, M. Juliana, Morgan, Cecilia A., Churchyard, Gavin, Baden, Lindsey R., Duerr, Ann C., Keefer, Michael C., Graham, Barney S., Nabel, Gary J.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society for Microbiology (ASM) 2010
الموضوعات:
Vaccines and Antiviral Agents
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC2798414/
https://ncbi.nlm.nih.gov/pubmed/19846512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00866-09
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة